DenCe-ctive – Use of autologous Thrombocytes for induction of Dendritic Cell activity
The therapeutic use of dendritic cells in vaccination
therapy requires prior activation of these immune cells. The invention exploits the ability of stimulated thrombocytes to activate dendritic cells ex vivo thereby offering the unique possibility of autologous activation. Immune therapy using activated dendritic cells is a well established approach used for various therapies including cancer vaccination strategies. An enormous market potential is expected. The invention provides the first method triggering an autologous maturation of dendritic cells into potent antigen presenting cells. Thus, the method constitutes a highly efficacious approach for inducing T-cell responses. The simple and efficient activation strategy is strikingly easy to handle and compatible with established immunotherapy protocols.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 0
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
New insights into the mechanisms of chromosome segregation errors
Research on centromere structure… Researchers from the Kops group in collaboration with researchers from the University of Edinburgh, made a surprising new discovery in the structure of the centromere, a structure…
“Topological hall effect” in two-dimensional quantum magnets
In a recent study published in Nature Physics, researchers from the Hefei Institutes of Physical Science of the Chinese Academy of Sciences, together with researchers of University of Science and Technology of China, have introduced the…
Coating Technologies of the Future
LZH and Cutting Edge Coatings at Optatec… At Optatec 2024, the Laser Zentrum Hannover e.V. (LZH) and Cutting Edge Coatings GmbH (CEC) present new opportunities in coating technologies for the…